1. Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In: Tuddenham EGD, Bloom AL, Forbes CD et al. Hemostasis and Thrombosis. Edinburg: Churchill Livingstone 1994: 1327–1333.
2. Anderson FA, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case–fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933–938.
3. Nordström M, Lindblad B, Berqvist D et al. A prospective study of the incidence od deep vein thrombosis with a defined urban population. J Intern Med 1992; 232: 155–160.
4. Silverstein MD, Heit JA, Mohr DN et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1998; 158: 585–593.
5. Virchow R Thrombose und Embolie. Vol Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Berlin: Verlag Maxirsch 1865: 219.
6. Bertina RM Molecular risk factors for thrombosis. Thromb Haemost 1999; 82: 601–609.
7. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients – the Sirius Study. Arch Intern Med 2000; 160: 3415–3420.
8. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610–619.
9. den Heyer M, Koster T, Bloom HJ et al. Hyperhomocysteinemia as a risk factor for deep–vein thrombosis. N Engl J Med 1996; 334: 759–762.
10. Koster T, Blann AD, BriËt E et al. Role of clotting factor VIII in effects of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152–155.
11. van Hylckama Vlieg A, van der Linden IK, Bertina RM et al. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678–3682.
12. Meijers JCM, Tekelenburg WLH, Bouma BN et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696–701.
13. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855–2859.
14. Egeberg O Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516–530.
15. Griffin JH, Evatt B, Zimmerman TS et al. Deficinecy of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370–1373.
16. Schwarz HP, Fisher M, Hapmeier P et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1994; 64: 1297–1300.
17. Comp PC, Nixon RR, Cooper MR et al. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082.
18. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525–1528.
19. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C; prediction of a cofactor
to activated protein C. Proc Natl Scad Sci USA 1993; 90: 1004–1008.
20. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associtated with resistance to activated protein C. Nature 1994; 369: 64–67.
21. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3’-untraslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an in venous thrombosis and an increase in venous thrombosis. Blood 1996; 88: 3698–3703.
22. Walker ID, Greaves M, Preston FE. Guideline. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512–528.
23. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia. Part I. Thromb Haemost 1996; 76: 651–652.
24. Mateo J, Oliver A, Borrell M et al. Laboratory evaluation and clinical characterisation of 2132 consecutive unselected patients with venous thromboembolism – results of the Spanish multicentre study
on thrombophilia (EMET – Study). Thromb Haemost 1997; 77: 444–451.
25. Heijboer H, Brandjes DPM, Büller HR et al. Deficiencies of coagulation inhibiting and fibrinolytic proteins in outpatients with deep vein thrombosis. N Engl J Med 1990; 332: 1512–1516.
26. Miletich JP, Sherman L, Broze GI. Absence of tbrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991–996.
27. Tait RC, Walker ID, Reitsma PH et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87–93.
28. Koster T, Rosendaal FR, BriËt E et al. Protein C deficiency in a controlled series of unselected outpatients. An infrequent but clear risk factor for venous thrombosis, Leiden Thrombophilia Study. Blood 1995; 85: 2756–2761.
29. Faioni EM, Valsecchi C, Palla A et al. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997; 78: 1343–1346.
30. Seligsohn U, Berger A, Abend M et al. Homozygous protein C deficiency manifested by massive venous thrombosis i the newborn. N Engl J Med l984; 310: 559–562.
31. McGehee WG, Klotz TA, Epstein DJ et al. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984; 101: 59–60.
32. Malm J, Laurell M, Nilsson IM et al. Thromboembolic disease – critical evaluation of laboratory investigation. Thromb Haemost 1992; 740: 9–15.
33. Svensson Pj, Dahlbäck B Resistance to activated protein C as a basis for thrombosis. N Engl J Med 1994; 330: 517–522.
34. Williamson D, Brown K, Luddigton et al. Factor V Cambridge: a new mutation (Arg 306-Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140–1144.
35. Bernardi F, Faioni EM, Castoldi E et al. A factor V genetic component differing from factor F R506Q contributes to activated protein C phenotype. Blood 1997; 90: 1552–1557.
36. Meinardi JR, Henkens CMA, Heringa MP et al. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practise. Blood Coag Fibrinol 1997; 8: 152–154.
37. Olivieri O, Friso S, Manzato F et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465–470.
38. Green D, Maliekel K, Sushko E et al. Activated protein C in cancer patients. Thromb Haemost 1997; Suppl: 316.
39. Mathonnet F, de Mazancourt P, Denninger MM et al. Role of factor VIII on activated protein C resistance ratio in inflammatory diseases. Br J Haematol 1996; 95: 423–425.
40. Dahlbäck B. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis. J Intern Med 1997; 242(Suppl 740): 1–8.
41. Nojima J, Kuratsune H, Suehisa E et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systematic lupus erythematosus. Br J Haematol 2002; 118: 57–83.
42. Svensson PJ, Zöller B, Dahlbäck B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected trombosis and in healthy controls. Thromb Haemost 1997; 77: 332.
43. de Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271–1276.
44. Rodeghiero F, Tosseto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643–650.
45. Chan WP, Lee CK, Kwong YL et al. A novel mutation of Arg 306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135.
46. Rosendaal FR, Doggen CJM, Zivelin A et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706–708.
47. Bertina RM. Genetic approach to thrombophilia. Thromb Haemost 2001; 86: 92–103.
48. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486–489.
49. Galli M, Comfurius P, Barbui T et al. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 217.
50. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 1444–1454.
51. Levine JS, Branch D, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752–763.
52. Ginsberg JS, Weles PS, Brill–Edwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685–3691.
53. Simioni P, Prandoni P, Zanon E ta al. Deep venous thrombosis and lupus anticoagulant. Thromb Haemost 1996; 76: 187–189.
54. O’Donnell J, Tuddenham EGD, Manning R et al. High prevalence of elevated F VIII levels in patients reffered for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825–828.
55. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen JC et al. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 1998; 79: 323–327.
56. Mansveld EPG, Laftan M, McVey JH et al. Analysis of the F8 gene in individuals with high plasma factor levels and associated venous thrombosis. Thromb Haemost 1998; 80: 561–565.
57. Kamphuisen PW, Eikenboom JCJ, Vos HL et al. Two highly variable CA repeat polymorphism in the factor VIII gene and the risk of venous thrombosis. Blood 1998; 90: 97a.
58. Falcon CR, Cattaneo M, Panzeri D et al. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080–1083.
59. Simioni P, Prandoni P, Burlina A et al. Hyperhomocysteinemia and deepvein thrombosis: a case control study. Thromb Haemost 1996; 76: 883–886.
60. Den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: a meta analysis. Thromb Haemost 1998; 80: 874–877.
61. D’Angelo A, Selhub J Homocysteine and thrombotic disease. Blood 1997; 90: 1–11.
62. Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458–462.
63. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thrombosis Research 1993; 71: 337–359.
64. Ubbink JB, Vermaak WJ, van der Merwe et al. Vitamin B12, vitamin B6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57: 47–53.
65. Engbertsen AMT, Franken DG, Boers GHJ et al. Thermolabile 5,10–methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142–150.
66. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–113.
67. Arruda V, von-Zuben P, Chiaparini L et al. The mutation Ala 677 Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818–821.
68. Salden A, Keeney S, Hay C et al. The C677T MTHFR variant and the risk of venous thrombosis (Letter). Br J Haematol 1997; 99: 472.
69. Tosseto A, Missiaglia E, Frezzato M et al. The VITA project: C677T mutation in the methylen – tetrahydrofolate reductase gene and the risk of venous thromboembolism. Br J Haematol 1997; 97: 804–806.
70. Brown K, Luddington R, Baglin T. Effect of the MTHFRC677T variant on the risk of venous thromboembolism: interaction with factor F V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998; 103: 42–44.